Macrophages, as central orchestrators of tissue homeostasis, exhibit remarkable developmental and functional plasticity across diverse physiological and pathological contexts. Mechanistically, microenvironmental cues govern phenotypic switching, while dysregulated crosstalk with stromal cells drives fibrosis and chronic inflammation. Emerging therapeutic strategies targeting macrophages demonstrate potential in restoring tissue homeostasis. However, challenges persist in achieving spatiotemporal precision and balancing pro-repair versus pro-fibrotic outcomes. This review synthesizes current understanding of macrophage biology, encompassing their developmental origins, phenotypic heterogeneity in tissue-specific niches, and multifaceted roles in extracellular matrix (ECM) remodeling, immune surveillance, and organ homeostasis. A comprehensive view of the macrophage regulatory landscape highlights that precise spatiotemporal regulation serves as the cornerstone for macrophages to restore tissue homeostasis. Multiple innovative strategies, including macrophage-based drug delivery systems, cellular and genetic engineering of macrophages, and synergistic macrophage treatment modalities, are expanding the technical frontiers for disease diagnosis and therapeutic intervention. Future directions emphasize integrating multi-omics profiling, synthetic biology, and AI-aided biomaterials to develop 'smart' therapeutics that dynamically steer macrophage functionality. Such synergy will unravel context-dependent signaling and subset-specific interactions, which further advances our understanding of macrophage biology and its translational potential in resolving refractory diseases, and bridges mechanistic insights into transformative clinical applications.
It suggests that a high leptin level may increase the risk of venous thromboembolism (VTE) in animal studies. However, clinical studies in this field are still largely unexplored. Our objective was to evaluate the relationship between the preoperative serum leptin levels and postoperative VTE incidence in osteoarthritis (OA) patients who underwent total knee arthroplasty (TKA) at our institute. We conducted a prospective and cross-sectional study in these OA patients from March 2014 to March 2016. Preoperative leptin levels were analyzed by Luminex assays. VTE was assessed preoperatively and on postoperative day 5 and 7. The potential risk factors for VTE were also documented. We enrolled 203 OA patients. No PE was detected and DVT was diagnosed in 34 patients postoperatively. There were significant differences between the median leptin levels in DVT group and non-DVT group [25.13 ng/mL (interquartile range, 14.51–44.31) vs 18.71 ng/mL (8.26–28.99), P = .007]. The relative risk of DVT significantly increased with natural logarithm (ln) leptin (per SD increase) (OR 2.37, 95% confidence interval (95% CI), 1.29–4.33, P = .005). Multivariate analyses adjusted for potential confounders showed ln leptin (per SD increase) was significantly associated with the relative risk of DVT (OR 2.17, 95% CI, 1.01–4.64, P = .046). When patients were subdivided into tertiles according to their leptin values, the OR for DVT increased with increasing tertiles of serum leptin (OR 1.03, 95% CI, 1.01–1.06, P for trend = .023). In the present study, our results indicate that a high preoperative leptin level may be an independent risk factor for postoperative DVT.
Ischemic heart disease (IHD) is the leading cause of death worldwide, accounting for over eight million deaths each year. IHD encompasses a spectrum of conditions, including atherosclerosis (AS), myocardial infarction (MI), and ischemia/reperfusion (I/R) injury. Programmed cell death (PCD) of endothelial cells (ECs) plays a critical role in IHD pathogenesis, causing microvascular dysfunction, barrier disruption and exacerbation of cardiac injury. PCD involves different signaling pathways, but they are interconnected. Therefore, it is crucial to understand the mechanisms underlying the various forms of PCD in ECs to develop therapeutic strategies for IHD. This review focuses on the molecular mechanisms of PCD of ECs in IHD and provides comprehensive summary of potential cell and gene therapy therapeutic strategies for the treatment of IHD.